ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity

US8835115B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• UNIVERSITAETSKLINIKUM FREIBURG · DE

Inventors

• William D. Figg · Fairfax, US
• Klaus Mross · Glückstadt, DE
• Dirk M. BEHRINGER · Bochum, DE
• Alex Sparreboom · Memphis, US
• Tristan M. Sissung · Annandale, US
• Stephan Mielke · Diepholz, DE

Key dates

• Filing date: Jul 13, 2007
• Grant date: Sep 16, 2014
• Expiry date: Jun 27, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/172
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.